Pharmacovigilance Programme of India

Authors

  • Duvvuru Ashok Kumar Department of Pharmacy Practice, P. Rami Reddy Memorial College of Pharmacy (Rajiv Gandhi Institute of Medical Sciences), Utukur, Kadapa, Andhra Pradesh, India
  • Languluri Reddenna Department of Pharmacy Practice, P. Rami Reddy Memorial College of Pharmacy (Rajiv Gandhi Institute of Medical Sciences), Utukur, Kadapa, Andhra Pradesh, India
  • Shaik Ayub Basha Department of Pharmacy Practice, P. Rami Reddy Memorial College of Pharmacy (Rajiv Gandhi Institute of Medical Sciences), Utukur, Kadapa, Andhra Pradesh, India

Abstract

 

Pharmacovigilance is defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, principally long term and short term adverse effects of medicines. It is an important and integral part of clinical research. India is the world’s second most populated country with over one billion potential drug consumers. Although, India is participating in the UMC program, its contribution to the UMC database is very little. This problem is essentially due to the absence of a robust ADR monitoring system and also the lack of awareness of reporting concept among Indian HCP. The specific aims of Pharmacovigilance are to advance patient care and safety in relation to the use of medicines and all medical and paramedical interventions, contribute to the assessment of benefit, harm, effectiveness, and risk of medicines, promising their safe, rational, and more effective  use, promote indulgent, education, and clinical training in Pharmacovigilance and its effective communication to the public. Pharmacovigilance methods must also be capable to designate which patients are at risk of developing an ADR. A suitably working Pharmacovigilance system is important if medicines are to be used cautiously. It will be advantage for healthcare professionals, regulatory authorities, pharmaceutical companies and the consumers. It aids pharmaceutical companies to monitor their medicines for risk.

 

Keywords: Adverse drug reaction, India, Pharmacovigilance, Uppsala monitoring centre

 

Downloads

Published

2019-07-18

Issue

Vol. 4 No. 3 (2014)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.